Published in Diabetes, Obesity and Metabolism (July 2026), this study is the largest real-world dataset yet linking carbohydrate restriction to kidney protection. Researchers matched 11,077 adults with type 2 diabetes or obesity enrolled in Virta Health's individualized nutrition therapy 1:1 against usual-care controls drawn from the Komodo Healthcare Map claims database, following both groups for up to five years.
Participants in the low-carbohydrate program had a lower incidence of new-onset CKD (10.1 vs. 15.6 cases per 1,000 person-years; HR 0.64, 95% CI 0.53-0.77), a 43% lower risk of reaching CKD stage 3 or higher (HR 0.57), and a 62% lower risk of advanced stage 4+ disease (HR 0.38). The advanced-CKD result rests on the fewest events and has the widest confidence interval.
Renal safety endpoints were reassuring: no increase in kidney stones, metabolic acidosis, diabetic ketoacidosis, or gout. Those are precisely the concerns most often raised about carbohydrate-restricted diets in kidney disease, and this cohort is large enough to detect them.
The population is type 2 diabetes and obesity, not ADPKD, so the results speak to carbohydrate restriction and kidney function generally rather than to cyst growth. They remain directly relevant to PKD patients: Thomas Weimbs — the lead ADPKD ketosis researcher — is a co-author, and the safety data address the main practical objection to a low-carb approach in kidney disease. The design is observational and claims-based, with diagnoses drawn from billing codes.